Keywords
fibrosis
metabolic syndrome
obesity
gene expression
How to Cite
Abstract
Non-alcoholic steatosis is generally associated with benign prognosis, however it can progress to fibrosis; the behavior of genes that contribute to their progression to fibrosis are not fully understood yet. The objective of this study was to analize the first signs of fibrogenesis in non-alcoholic steatosis in obese versus non-obese patients. A prospective descriptive study included patients with non-alcoholic steatosis was performed. The patients were divided in two groups, obese and non-obese. Sociodemographic, anthropometric and the suffering of the components of metabolic syndrome information were obtained. Biochemical parameters and expression leves of theTNF-α, NF-kβ, CYP2E1, TGF-β, OPN, COL4α5 and HGF genes were determined by RT-PCR. Our results showed significant differences in the levels of expression of the CYP2E1 gene, the level of expression being higher in obese patients suffering from complete metabolic syndrome. Furthermore, in non-obese patients with steatosis and without components of the metabolic syndrome, TGF-β is activated as a participant in fibrogen pathways and in obese patients with complete metabolic syndrome, the significant expression level of CYP2E1 could indicate an alarm signal for possible progress of the illness. Special attention and monitoring of steatosis should be paid in obese patients.References
Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016; 65(8): 1017-25. Doi: http://dx.doi.org/10.1016/j.metabol.2016.01.012.
Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018; 75(18): 3313-27. Doi: http://dx.doi.org/10.1007/s00018-018-2860-6.
McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol. 2015; 62(5): 1148-55. Doi: http://dx.doi.org/10.1016/j.jhep.2014.11.034.
Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010; 59(7): 969-74. Doi: http://dx.doi.org/10.1136/gut.2009.205088.
Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013; 59(3): 550-6. Doi: http://dx.doi.org/10.1016/j.jhep.2013.04.027.
Di Costanzo A, D'Erasmo L, Polimeni L, Baratta F, Coletta P, Di Martino M, et al. Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage. Atherosclerosis. 2017; 257: 232-9. Doi: http://dx.doi.org/10.1016/j.atherosclerosis.2016.12.018.
Cayon A, Crespo J, Guerra AR, Pons-Romero F. Gene expression in obese patients with non-alcoholic steatohepatitis. Rev Esp Enferm Dig. 2008; 100(4): 212-8. Doi: http://dx.doi.org/10.4321/s1130-01082008000400004.
Walton KL, Johnson KE, Harrison CA. Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis. Front Pharmacol. 2017; 8: 461. Doi: http://dx.doi.org/10.3389/fphar.2017.00461.
Aljomah G, Baker S, Liu W, Kozielski R, Oluwole J, Lupu B, et al. Induction of CYP2E1 in non-alcoholic fatty liver diseases. Exp Mol Pathol. 2015; 99(3): 677-81. Doi: http://dx.doi.org/10.1016/j.yexmp.2015.11.008.
Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5): 1705-25. Doi: http://dx.doi.org/10.1053/gast.2002.36572.
Mustapic S, Ziga S, Matic V, Bokun T, Radic B, Lucijanic M, et al. Ultrasound Grade of Liver Steatosis Is Independently Associated with the Risk of Metabolic Syndrome. Can J Gastroenterol Hepatol. 2018; 2018: 8490242. Doi: http://dx.doi.org/10.1155/2018/8490242.
Lambis L, Solana J, Gastelbondo B, Romero D, Garrido D, Puello W, et al. Factores de riesgo asociados a hígado graso de origen no alcohólico en una población del Caribe Colombiano. Rev Colomb de Gastroenterol. 2016; 31(2): 89-95. Doi: http://dx.doi.org/10.22516/25007440.77.
Madera M, González F, Romero D, Suárez A. Expresión Génica del Factor de Crecimiento Transformante Beta en Niños con Fisura Labio Palatina no Sindrómica. Int J Odontostomat. 2016; 10(1): 75-84. Doi: http://dx.doi.org/10.4067/S0718-381X2016000100013.
Ochoa CE, Calambás F. Hígado graso no alcohólico en consulta de gastroenterología. Repert Med Cir. 2017; 26(4): 225-30. Doi: http://dx.doi.org/10.1016/j.reper.2017.10.005.
Kur P, Kolasa-Wołosiuk A, Misiakiewicz-Has K, Wiszniewska B. Sex Hormone-Dependent Physiology and Diseases of Liver. Int J Environ Res Public Health. 2020; 17(8): 2620. Doi: http://dx.doi.org/10.3390/ijerph17082620.
Zhang H, Liu Y, Wang L, Li Z, Zhang H, Wu J, et al. Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat. J Lipid Res. 2013; 54(2): 345-57. Doi: http://dx.doi.org/10.1194/jlr.M028969.
Sweet P, Khoo T, Nguyen S. Nonalcoholic Fatty Liver Disease. Prim Care. 2017; 44(4): 599-607. Doi: http://dx.doi.org/10.1016/j.pop.2017.07.003.
Katikireddi SV, Whitley E, Lewsey J, Gray L, Leyland AH. Socioeconomic status as an effect modifier of alcohol consumption and harm: analysis of linked cohort data. Lancet Public Health. 2017; 2(6): e267-e76. Doi: http://dx.doi.org/10.1016/s2468-2667(17)30078-6.
De la Espriella Guerrero RA, Rodriguez V, Rincón CJ, Morales DC, Rodríguez SJ, Gómez-Restrepo C. Consumo de alcohol en la población colombiana. Encuesta Nacional de Salud Mental 2015. Rev Colomb Psiquiatr. 2016; 45(1): 76-88. Doi: http://dx.doi.org/10.1016/j.rcp.2016.05.002.
Pérez-Gómez A, Lanziano C, Reyes-Rodríguez MF, Mejía-Trujillo J, Cardozo-Macías F. Perfiles asociados al consumo de alcohol en adolescentes colombianos. Acta Colomb de Psicol. 2018; 21(2): 258-69. Doi: http://dx.doi.org/10.14718/ACP.2018.21.2.12.
Lee K, Sung J, Kim J, Park T. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev. 2009; 25(2): 150-5. Doi: http://dx.doi.org/10.1002/dmrr.924.
Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep. 2019; 1(6): 468-79. Doi: http://dx.doi.org/10.1016/j.jhepr.2019.10.008.
Pantsari MW, Harrison SA. Nonalcoholic Fatty Liver Disease Presenting With an Isolated Elevated Alkaline Phosphatase. J Clin Gastroenterol. 2006; 40(7): 633-5. Doi: http://dx.doi.org/10.1097/00004836-200608000-00015.
Vendhan R, Amutha A, Anjana RM, Unnikrishnan R, Deepa M, Mohan V. Comparison of Characteristics Between Nonobese and Overweight/Obese Subjects with Nonalcoholic Fatty Liver Disease in a South Indian population. Diabetes Technol Ther. 2014; 16(1): 48-55. Doi: http://dx.doi.org/10.1089/dia.2013.0165.
Kwak J, Jun D, Lee S, Cho Y, Lee K, Lee H, et al. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: A cross-sectional study. Clin Nutr. 2018; 37(5): 1550-7. Doi: http://dx.doi.org/10.1016/j.clnu.2017.08.018.
Hennig EE, Mikula M, Goryca K, Paziewska A, Ledwon J, Nesteruk M, et al. Extracellular matrix and cytochrome P450 gene expression can distinguish steatohepatitis from steatosis in mice. J Cell Mol Med. 2014; 18(9): 1762-72. Doi: http://dx.doi.org/10.1111/jcmm.12328.
Kwon OW, Jun DW, Lee SM, Lee KN, Lee HL, Lee OY, et al. Carbohydrate but not fat is associated with elevated aminotransferases. Aliment Pharmacol Ther. 2012; 35(9): 1064-72. Doi: http://dx.doi.org/10.1111/j.1365-2036.2012.05061.x.
Seo YY, Cho YK, Bae J-C, Seo MH, Park SE, Rhee E-J, et al. Tumor Necrosis Factor-α as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study. Endocrinol Metab (Seoul). 2013; 28(1): 41-5. Doi: http://dx.doi.org/10.3803/EnM.2013.28.1.41.
Tan Y, Kim J, Cheng J, Ong M, Lao W-G, Jin X-L, et al. Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats. World J Gastroenterol. 2017; 23(21): 3805-14. Doi: http://dx.doi.org/10.3748/wjg.v23.i21.3805.
Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, et al. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2014; 59(2): 483-95. Doi: http://dx.doi.org/10.1002/hep.26698.
De Lédinghen V, Liu H, Zhang F, Lo CR, Subbaramaiah K, Dannenberg AJ, et al. Induction of cyclooxygenase-2 by tumor promoters in transformed and cytochrome P450 2E1-expressing hepatocytes. Carcinogenesis. 2002; 23(1): 73-9. Doi: http://dx.doi.org/10.1093/carcin/23.1.73.
Wen Y, Jeong S, Xia Q, Kong X. Role of Osteopontin in Liver Diseases. Int J Biol Sci. 2016; 12(9): 1121-8. Doi: http://dx.doi.org/10.7150/ijbs.16445.
Suárez-Causado A, Caballero-Díaz D, Bertrán E, Roncero C, Addante A, García-Álvaro M, et al. HGF/c-Met signaling promotes liver progenitor cell migration and invasion by an epithelial-mesenchymal transition-independent, phosphatidyl inositol-3 kinase-dependent pathway in an in vitro model. Biochim Biophys Acta. 2015; 1853(10 Pt A): 2453-63. Doi: http://dx.doi.org/10.1016/j.bbamcr.2015.05.017
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2021 Universidad del Magdalnea